DK1339406T3 - Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet - Google Patents

Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet

Info

Publication number: DK1339406T3
Authority: DK; Denmark
Prior art keywords: processes; preparation; treatment; nervous system; central nervous
Prior art date: 2000-11-28

Application number

DK01986458T

Other languages

English (en)

Inventor

Wayne Everett Childers

Michael Gerard Kelly

Sharon Joy Rosenzweig-Lipson

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2001-11-27

Publication date

2004-09-27

2001-11-27 Application filed by Wyeth Corp filed Critical Wyeth Corp

2004-09-27 Application granted granted Critical

2004-09-27 Publication of DK1339406T3 publication Critical patent/DK1339406T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK01986458T 2000-11-28 2001-11-27 Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet DK1339406T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25330100P	2000-11-28	2000-11-28
US29781401P	2001-06-13	2001-06-13

Publications (1)

Publication Number	Publication Date
DK1339406T3 true DK1339406T3 (da)	2004-09-27

Family

ID=26943115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01986458T DK1339406T3 (da)	2000-11-28	2001-11-27	Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet

Country Status (25)

Country	Link
US (3)	US6469007B2 (da)
EP (1)	EP1339406B1 (da)
JP (1)	JP4198989B2 (da)
KR (1)	KR100835552B1 (da)
CN (1)	CN100352437C (da)
AR (1)	AR035603A1 (da)
AT (1)	ATE269078T1 (da)
AU (2)	AU3765402A (da)
BR (1)	BR0115609A (da)
CA (1)	CA2428039C (da)
DE (1)	DE60103927T2 (da)
DK (1)	DK1339406T3 (da)
EA (1)	EA005925B1 (da)
ES (1)	ES2222401T3 (da)
HK (1)	HK1057864A1 (da)
HU (1)	HUP0400551A2 (da)
IL (1)	IL156098A0 (da)
MX (1)	MXPA03004677A (da)
NO (1)	NO325501B1 (da)
NZ (1)	NZ526150A (da)
PL (1)	PL363219A1 (da)
PT (1)	PT1339406E (da)
TR (1)	TR200401546T4 (da)
TW (1)	TWI224102B (da)
WO (1)	WO2002044142A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432826B1 (en) *	1999-11-29	2002-08-13	Applied Materials, Inc.	Planarized Cu cleaning for reduced defects
US20060223824A1 (en) *	2000-11-28	2006-10-05	Wyeth	Serotonergic agents
US20060287335A1 (en) *	2000-11-28	2006-12-21	Wyeth	Serotonergic agents for treating sexual dysfunction
EP1408976B3 (en)	2001-07-20	2010-08-25	Psychogenics Inc.	Treatment for attention-deficit hyperactivity disorder
US7361773B2 (en)	2002-03-12	2008-04-22	Wyeth	Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
MXPA04008730A (es)	2002-03-12	2004-12-06	Wyeth Corp	Proceso para preparacion de piperazinas quirales 1,4-disustituidas.
US7091349B2 (en)	2002-03-12	2006-08-15	Wyeth	Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
IL163827A0 (en)	2002-03-12	2005-12-18	Wyeth Corp	Process for synthesizing chiral n-aryl piperazines
GB0219961D0 (en) *	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US20040192730A1 (en) *	2003-03-13	2004-09-30	Dynogen Pharmaceuticals, Inc.	Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
PA8626301A1 (es) *	2004-03-19	2006-12-07	Wyeth Wyeth	Proceso para preparar derivados de n-aril-piperazina
US20070099931A1 (en) *	2004-03-19	2007-05-03	Wyeth	Pharmaceutical dosage forms and compositions
US20050215561A1 (en) *	2004-03-19	2005-09-29	Krishnendu Ghosh	Pharmaceutical dosage forms and compositions
KR100646337B1 (ko) *	2004-06-30	2006-11-23	주식회사 롯데기공	보일러의 누수 감지방법
ATE469174T1 (de) *	2004-10-15	2010-06-15	Us Gov Health & Human Serv	Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
AU2006218845A1 (en) *	2005-03-01	2006-09-08	Wyeth	Crystalline and amorphous 4-cyano-N{(2R)-2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin-1-yl)-propyl}-N-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2006138549A1 (en) *	2005-06-17	2006-12-28	Wyeth	Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
EP1993527A4 (en) *	2006-01-26	2009-08-05	Univ Rochester	INHIBITION OF AMYLOID BETA PEPTIDE / RAGE INTERACTION AT BLOOD BRAIN BARRIER
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200831096A (en) *	2006-11-28	2008-08-01	Wyeth Corp	Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
CL2008000119A1 (es)	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
WO2009129263A1 (en) *	2008-04-15	2009-10-22	The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv.	Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL101722A (en)	1991-05-02	1996-05-14	Wyeth John & Brother Ltd	History of piperazine, their preparation and pharmaceutical preparations containing them
GB9514901D0 (en)	1995-07-20	1995-09-20	American Home Prod	Piperazine derivatives

2001
- 2001-11-13 US US10/010,575 patent/US6469007B2/en not_active Expired - Fee Related
- 2001-11-27 AT AT01986458T patent/ATE269078T1/de not_active IP Right Cessation
- 2001-11-27 PT PT01986458T patent/PT1339406E/pt unknown
- 2001-11-27 PL PL01363219A patent/PL363219A1/xx not_active Application Discontinuation
- 2001-11-27 KR KR1020037007064A patent/KR100835552B1/ko not_active IP Right Cessation
- 2001-11-27 ES ES01986458T patent/ES2222401T3/es not_active Expired - Lifetime
- 2001-11-27 WO PCT/US2001/043160 patent/WO2002044142A2/en active IP Right Grant
- 2001-11-27 AR ARP010105502A patent/AR035603A1/es not_active Application Discontinuation
- 2001-11-27 DK DK01986458T patent/DK1339406T3/da active
- 2001-11-27 TR TR2004/01546T patent/TR200401546T4/xx unknown
- 2001-11-27 JP JP2002546512A patent/JP4198989B2/ja not_active Expired - Fee Related
- 2001-11-27 HU HU0400551A patent/HUP0400551A2/hu unknown
- 2001-11-27 DE DE60103927T patent/DE60103927T2/de not_active Expired - Lifetime
- 2001-11-27 CN CNB018196853A patent/CN100352437C/zh not_active Expired - Fee Related
- 2001-11-27 NZ NZ526150A patent/NZ526150A/en unknown
- 2001-11-27 AU AU3765402A patent/AU3765402A/xx active Pending
- 2001-11-27 TW TW090129285A patent/TWI224102B/zh not_active IP Right Cessation
- 2001-11-27 IL IL15609801A patent/IL156098A0/xx unknown
- 2001-11-27 EP EP01986458A patent/EP1339406B1/en not_active Expired - Lifetime
- 2001-11-27 AU AU2002237654A patent/AU2002237654B2/en not_active Ceased
- 2001-11-27 EA EA200300619A patent/EA005925B1/ru not_active IP Right Cessation
- 2001-11-27 BR BR0115609-8A patent/BR0115609A/pt not_active Application Discontinuation
- 2001-11-27 MX MXPA03004677A patent/MXPA03004677A/es active IP Right Grant
- 2001-11-27 CA CA2428039A patent/CA2428039C/en not_active Expired - Fee Related
2002
- 2002-08-14 US US10/218,251 patent/US6586436B2/en not_active Expired - Fee Related
2003
- 2003-05-20 US US10/441,536 patent/US7026320B2/en not_active Expired - Fee Related
- 2003-05-27 NO NO20032390A patent/NO325501B1/no not_active IP Right Cessation
2004
- 2004-02-04 HK HK04100730A patent/HK1057864A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60103927D1 (de)	2004-07-22
EP1339406A2 (en)	2003-09-03
NO325501B1 (no)	2008-05-26
CA2428039A1 (en)	2002-06-06
US7026320B2 (en)	2006-04-11
US6586436B2 (en)	2003-07-01
NO20032390D0 (no)	2003-05-27
CA2428039C (en)	2011-08-09
AU2002237654B2 (en)	2005-07-28
AR035603A1 (es)	2004-06-16
JP2004520289A (ja)	2004-07-08
US6469007B2 (en)	2002-10-22
JP4198989B2 (ja)	2008-12-17
WO2002044142A2 (en)	2002-06-06
CN1477961A (zh)	2004-02-25
MXPA03004677A (es)	2003-09-05
US20020107254A1 (en)	2002-08-08
HK1057864A1 (en)	2004-04-23
HUP0400551A2 (en)	2006-02-28
NO20032390L (no)	2003-07-22
TR200401546T4 (tr)	2004-09-21
CN100352437C (zh)	2007-12-05
EA005925B1 (ru)	2005-08-25
KR20030051879A (ko)	2003-06-25
TWI224102B (en)	2004-11-21
BR0115609A (pt)	2003-11-11
ATE269078T1 (de)	2004-07-15
US20030216408A1 (en)	2003-11-20
ES2222401T3 (es)	2005-02-01
US20030022901A1 (en)	2003-01-30
PL363219A1 (en)	2004-11-15
EA200300619A1 (ru)	2003-10-30
KR100835552B1 (ko)	2008-06-09
IL156098A0 (en)	2003-12-23
PT1339406E (pt)	2004-10-29
EP1339406B1 (en)	2004-06-16
WO2002044142A3 (en)	2002-08-08
AU3765402A (en)	2002-06-11
DE60103927T2 (de)	2005-06-23
NZ526150A (en)	2004-11-26

Publication	Publication Date	Title
DK1339406T3 (da)	2004-09-27	Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DK1063990T3 (da)	2007-05-21	Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1345910T3 (da)	2009-07-20	Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
IS6560A (is)	2002-09-20	Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DK1459750T3 (da)	2005-08-15	(S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DK1156813T3 (da)	2008-10-13	Reovirus til behandling af cellulære proliferative lidelser
EE200100441A (et)	2002-12-16	Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
DK1474416T3 (da)	2008-01-14	Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1343773T3 (da)	2007-02-05	Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
EE200300167A (et)	2003-08-15	Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
NO20043085L (no)	2004-07-13	Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DK1282616T3 (da)	2004-09-20	Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1228028T3 (da)	2005-11-14	Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK2189162T3 (da)	2014-02-03	Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK0908458T3 (da)	2006-06-06	Substituerede pyridylmethylpiperazin- og piperidinderivater, deres fremstilling samt deres anvendelse til behandling af lidelser i centralnervesystemet (CNS)
NO20023448D0 (no)	2002-07-18	Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
DK1309322T3 (da)	2006-10-23	Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1257278T3 (da)	2006-06-12	Anvendelse af mirtazapin til behandling af sövnforstyrrelser
ATE292107T1 (de)	2005-04-15	Verwendung von carbonylaminoderivaten gegen zentralnervensystem-störungen
NO20033120D0 (no)	2003-07-08	2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
MXPA03004190A (es)	2003-09-22	Tratamiento de trastornos de ansiedad.
ATE374197T1 (de)	2007-10-15	Indolderivate zur behandlung von erkrankungen des zentralnervensystems
DK1341758T3 (da)	2006-10-30	Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1468686T3 (da)	2007-03-12	S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser